联川生物北交所IPO：71岁副董事长周小川持股21%，拥有美国永居权

Core Viewpoint - Lianchuan Biotechnology Co., Ltd. has been accepted for IPO on the Beijing Stock Exchange, after previously withdrawing its application for the Sci-Tech Innovation Board due to future issuance plans [2] Financial Performance - Revenue for Lianchuan Biotechnology is projected to grow from 235 million yuan in 2022 to 367 million yuan in 2024, representing a compound annual growth rate (CAGR) of approximately 25.5% [2] - Net profit is expected to increase from 52.76 million yuan in 2022 to 60.06 million yuan in 2024, indicating a growth rate of about 13.5% [2] - Gross profit margin is forecasted to decline from 54.31% in 2022 to 48.73% in 2024 [2] Shareholder Structure - The controlling shareholders of Lianchuan Biotechnology are Lang Qiulei and Zhou Xiaochuan, who collectively control 48.79% of the company [3] - Lang Qiulei directly holds 17.23% of the shares and indirectly controls an additional 10.32% through Lianchuan Investment, while Zhou Xiaochuan directly holds 21.25% [3] Corporate Governance - Lang Qiulei and Zhou Xiaochuan have signed multiple agreements to ensure their joint control over the company, including a commitment to exercise voting rights in a unified manner [4] - The stability of the actual control of the company has been further reinforced through a commitment letter signed in April 2025 [4] Leadership Background - Lang Qiulei, born in 1979, has held various positions within the company since its establishment in 2006, currently serving as the Chairman and General Manager [5] - Zhou Xiaochuan, born in 1954, has extensive experience in research and management roles, currently serving as the Vice Chairman of Lianchuan Biotechnology [6]